Drugs / FH-MCVA2TCR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03747484 | Jul 2019 → Jan 2024 | — | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FH-MCVA2TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03747484 ↗ |
| Modality | Cell therapy | “gene-modified immune cells (FH-MCVA2TCR)” NCT03747484 ↗ |
| Route | Intravenous | “Patients receive FH-MCVA2TCR T-cells intravenously (IV)” NCT03747484 ↗ |